Novo Nordisk says diabetes drug semaglutide cuts heart risk by 26 percent

COPENHAGEN (Reuters) - Novo Nordisk's experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent in a keenly awaited clinical, according to results released on Friday.